Meso Scale Discovery Sector 6000 Imager

描述（由申请人提供）：本提案要求提供资金，用于购买Meso Scale Discovery SECTOR 6000成像仪，用于通过单重和多重形式的直接夹心免疫测定法检测生物标志物。Meso Scale Discovery生物标志物检测技术基于电化学发光，可实现对检测反应的统一控制、增强的灵敏度和较大的动态信号范围。所要求的仪器将满足在涉及婴儿和儿童的临床和转化研究中检测小样本量的多种生物标志物的日益增长的需求。所要求的仪器利用超低噪声电荷耦合器件（CCD）相机，用于快速检测电致发光生物标志物检测反应中产生的信号。该仪器能够以单孔、4孔、7孔或10孔的形式测量各种各样的分析物（激素、细胞因子、生长因子、疾病标志物）。该仪器将支持七个主要项目和八个其他项目的研究，该仪器将被纳入临床和转化研究中心的转化核心实验室，为CHOP进行的临床和转化研究提供持续的实验室支持。作为转化核心实验室提供的服务的一部分，将收取用户费用，以帮助支付与仪器相关的消耗品、试剂和维护费用。该仪器将有助于推进以下疾病领域的临床和转化研究：先天性高胰岛素血症，1型糖尿病，克罗恩病和肾移植中的骨健康，青少年肥胖，儿科2型糖尿病，囊性纤维化和青少年类风湿性关节炎。总体而言，多重免疫分析平台将扩大我们为用户群体提供不同生物标志物水平分析的能力，并使我们能够显著减少这些分析所需的样本量，这一功能对婴儿和儿童尤为重要。拟议的设备还将扩大我们设计新生物标志物检测的能力，这对临床和转化研究至关重要。

DESCRIPTION (provided by applicant): This proposal requests funds for the acquisition of a Meso Scale Discovery SECTOR 6000 Imager for the detection of biomarkers by direct sandwich immunoassay in single and multiplex formats. The Meso Scale Discovery biomarker detection technology is based on electrochemiluminescence, which allows uniform control of the detection reaction, enhanced sensitivity, and a large dynamic signal range. The requested instrumentation will meet the growing demand for detection of multiple biomarkers in small sample volumes for clinical and translational research involving infants and children. The requested instrument utilizes an ultra-low noise charge-coupled device (CCD) camera for rapid detection of signal generated in an electrochemiluminescent biomarker detection reaction. The instrument is capable of measuring a wide variety of analytes (hormones, cytokines, growth factors, disease markers) in a single, 4-, 7- or 10-plex/well format. The instrument will support the research of seven major projects and eight other projects and the instrument will be incorporated into the Translational Core Laboratory of the Clinical and Translational Research Center, which provides ongoing laboratory support for clinical and translational research conducted at CHOP. As part of the services offered by the Translational Core Laboratory, user fees will be collected to help defray the costs of consumables, reagents, and maintenance related to the instrument. The instrument will help to advance clinical and translational research in the following disease areas: congenital hyperinsulinism, type 1 diabetes, bone health in Crohn's disease and renal transplantation, adolescent obesity, pediatric type 2 diabetes, cystic fibrosis, and juvenile rheumatoid arthritis. Overall, the multiplex immunoassay platform will expand our capacity to provide analysis of different biomarker levels for the user community, and will enable us to significantly reduce the sample volumes needed for these analyses, a feature that is particularly important for infants and children. The proposed equipment will also expand our capability to design assays for new biomarkers, which is extremely important for clinical and translational research.